Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
Conclusion An emerging and promising approach in SCD management involves harnessing endogenous clearance mechanisms for hemolysis products
Acknowledgements The study is supported by a Singapore EDB-IPP grant (grant number: RL2012035)
The treatment is performed in a clinical setting under proper medical supervision
Given recent clinical findings and evidences, in this context glucagon-like peptide-1 receptor agonist is currently available as a candidate that is clinically positioned as a first-line anti-obesity agent for the effective prevention of ORCVDs in people with obesity
Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis
US$ 29.37
US$ 28.65
US$ 26.50
US$ 25.43
